저분자량 헤파린 시장 : 약물별, 포장별, 용도별, 최종사용자별, 지역별

Low Molecular Weight Heparin Market is estimated to be valued at USD 5,073.90 Mn in 2026 and is expected to reach USD 8,008.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 6.7% from 2026 to 2033.

Low Molecular Weight Heparins (LMWH) are a form of pharmacological anticoagulant intervention which are derived from unfractionated heparin (UFH) by chemical or enzymatic depolymerisation to yield fragments that are around one third the size of heparin. Low molecular weight heparin is used for prophylaxis of deep vein thrombosis and pulmonary embolism, or thrombosis occurring in a broad spectrum of clinical indications, including general or orthopaedic surgery, neurosurgery, trauma, unstable angina, and myocardial infarction. LMWHs are however, associated with higher anticoagulant effect and provides higher bioavailability after subcutaneous administration, as compared to unfractionated heparin UFH, for thromboembolic indications. Low molecular weight heparin is the most suitable anticoagulant in case of complicated pregnancy, as it eliminates risk of crossing the placental membrane. Low-molecular-weight heparins (LMWHs), for example, dalteparin, enoxaparin, among others, are anticoagulants. Low molecular weight heparins administration is via subcutaneous injection; this has long-term implications on the choice of anticoagulant for prophylaxis, for example, in orthopedic patients recovering from joint replacement surgery or in the treatment of Deep Vein Thrombosis and Pulmonary Embolism (DVT/PE). Patients often dislike injections, especially self-administered ones, complaining of pain or bleeding with injection, and prefer an oral alternative.

Market Dynamics

Increasing number of people are being affected with Deep Vein Thrombosis (DVT) which will subsequently increase demand for Low Molecular Weight Heparins (LMWH). For instance, according to National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention (CDC), Furthermore, in July 2021, according to Centers for disease control and prevention, the precise number of people affected by deep vein thrombosis (DVT) or pulmonary embolism (PE) is unknown, although as many as 900,000 people could be affected each year in the United States. Estimates suggest that 60,000-100,000 American citizens in 2019 die of DVT/PE (also called venous thromboembolism, or VTE). A case study published in April 2017 in the Canadian Medical Association Journal noted that the risk of venous thromboembolism (VTE), which includes both DVT and pulmonary embolism (PE), increases 20-fold in male-to-female people using hormone treatment, especially estrogen. A meta-analysis published in 2019 in the Journal of Blood Medicine reviewed 13 studies that looked at the effects of hormone therapy, including which types of estrogen are used, on transgender men and women. It found that even though the risk of VTE increased with certain formulations of hormone therapy, the absolute clinical risk is low.

Key features of the study

• This report provides an in-depth analysis of the global low molecular weight heparin market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global low molecular weight heparin market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer, Inc., LEO Pharma A/S, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, Changzhou Qianhong Biopharma, and Intrapharm Laboratories.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global low molecular weight heparin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global low molecular weight heparin market

Market Segmentation

• By Drug
  • Enoxaparin
  • Dalteparin
  • Nadroparin
  • Bemiparin
  • Tinzaparin
  • Others
• By Packaging
  • Multi-vials
  • Prefilled Syringes
• By Application
  • Deep Vein Thrombosis
  • Acute Coronary Syndrome (ACS)
  • Pulmonary Embolism
  • Atrial Fibrillation
• By End User
  • Hospitals
  • Private
  • Public
  • Clinics
  • Home
• By Region
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa
  • GCC Countries
  • Israel
  • Rest of Middle East & Africa
• Key Players
  • Pfizer, Inc.
  • LEO Pharma A/S
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Amphastar Pharmaceuticals Inc.
  • Abbott Laboratories
  • Aspen Pharmacare Holdings
  • Laboratorios Farmaceuticos ROVI SA
  • Changzhou Qianhong Biopharma
  • Intrapharm Laboratories

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug
  • Market Snapshot, By Packaging
  • Market Snapshot, By Application
  • Market Snapshot, By End User
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Epidemiology
• Key Developments
• Strategic Acquisitions
• Advantages of LMWH over UFH
• Cost-effectiveness of LMWH vs. UFH
• Shortage of Enoxaparin & Estimated Resupply Dates
• Drug Delivery Systems
• Regulatory Scenario
• Reimbursement Scenario
• Buy-and-bill and White Bagging Channel
• PEST Analysis

4. Global Low Molecular Weight Heparin Market, By Drug, 2026 - 2033, (USD Mn)

• Overview
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Enoxaparin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Dalteparin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Nadroparin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Bemiparin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Tinzaparin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

5. Global Low Molecular Weight Heparin Market, By Packaging, 2026 - 2033, (USD Mn)

• Overview
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Multi-vials
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Prefilled Syringes
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

6. Global Low Molecular Weight Heparin Market, By Application, 2026 - 2033, (USD Mn)

• Overview
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Deep Vein Thrombosis
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Acute Coronary Syndrome (ACS)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Pulmonary Embolism
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Atrial Fibrillation
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

7. Global Low Molecular Weight Heparin Market, By End User, 2026 - 2033, (USD Mn)

• Overview
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Hospitals
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Private
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Public
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Clinics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Home
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

8. Global Low Molecular Weight Heparin Market, By Region, 2026 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2026-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Packaging, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Packaging, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2026 - 2033, Market Size and Forecast, and Y-o-Y Growth, By Drug, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Packaging, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Packaging, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Packaging, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Packaging, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Heat Map Analysis
• Company Profiles
  • Pfizer, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Key Strategies
  • LEO Pharma A/S
    • Company Overview
    • Drug Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Key Strategies
  • Sanofi S.A.
    • Company Overview
    • Drug Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Key Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Drug Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Key Strategies
  • Amphastar Pharmaceuticals Inc.
    • Company Overview
    • Drug Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Key Strategies
  • Aspen Pharmacare Holdings
    • Company Overview
    • Drug Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Key Strategies
  • Laboratorios Farmaceuticos ROVI SA
    • Company Overview
    • Drug Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Key Strategies
  • Changzhou Qianhong Biopharma
    • Company Overview
    • Drug Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Key Strategies
  • Intrapharm Laboratories
    • Company Overview
    • Drug Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Key Strategies

10. Section

• References
• Research Methodology
• About Us and Sales Contact